C. Blajman

Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer

Marshall R. Posner, Diáne Hershock, C. Blajman et al. · New England Journal of Medicine · 2007 · 1.7K citations · Full text

Medicine, Oncology, Chemotherapy +8

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial

Jan B. Vermorken, Jan Stöhlmacher-Williams, Lisa Licitra et al. · The Lancet Oncology · 2013 · 433 citations · Full text

Medicine, Oncology, Chemotherapy +10

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

Jin Soo Lee, Vera Hirsh, Keunchil Park et al. · Journal of Clinical Oncology · 2012 · 231 citations

Medicine, Oncology, Pharmacology +10

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

Marshall R. Posner, Charles M. Norris, Lori J. Wirth et al. · Annals of Oncology · 2009 · 152 citations · Full text

Medicine, Oncology, Surgery +17